Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,463
  • Shares Outstanding, K 4,556
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,670 K
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +188,590.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.02 +4.48%
on 11/18/19
10.89 -61.43%
on 11/05/19
-2.18 (-34.17%)
since 10/18/19
3-Month
4.02 +4.48%
on 11/18/19
10.89 -61.43%
on 11/05/19
-3.74 (-47.14%)
since 08/16/19
52-Week
4.02 +4.48%
on 11/18/19
94.00 -95.53%
on 12/04/18
-78.30 (-94.91%)
since 11/16/18

Most Recent Stories

More News
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

- Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End -

SLS : 4.20 (-18.45%)
SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...

SLS : 4.20 (-18.45%)
SELLAS Announces Reverse Stock Split

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...

SLS : 4.20 (-18.45%)
Patients Turn to Advanced Technology in Order to Combat Cancer

Over the past two decades, cancer-related deaths in the U.S. have declined significantly. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American...

ONPH : 0.0299 (-0.33%)
INO : 2.28 (-2.98%)
REGN : 340.19 (-1.36%)
AVEO : 0.66 (+4.40%)
SLS : 4.20 (-18.45%)
NWBO : 0.2200 (-0.99%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

FinancialBuzz.com News Commentary

ADXS : 0.50 (+26.57%)
GERN : 1.27 (-3.05%)
SLS : 4.20 (-18.45%)
ONPH : 0.0299 (-0.33%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...

ONPH : 0.0299 (-0.33%)
KDMN : 4.13 (+5.36%)
ADXS : 0.50 (+26.57%)
SLS : 4.20 (-18.45%)
GERN : 1.27 (-3.05%)
Technological Advancements Aid Medical Practitioners in Combatting Cancer

In 2018, there was an estimated 1.73 million new cancer cases diagnosed and 609,640 cancer deaths in the U.S., according to the American Cancer Society. The ACS does not expect cancer rates to slow down...

ONPH : 0.0299 (-0.33%)
UEEC : 1.3500 (+8.43%)
AVEO : 0.66 (+4.40%)
APVO : 0.62 (unch)
SLS : 4.20 (-18.45%)
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results

EQNX::TICKER_START (NASDAQ:SLS), EQNX::TICKER_END

SLS : 4.20 (-18.45%)
SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...

SLS : 4.20 (-18.45%)
SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA(R) (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement -

SLS : 4.20 (-18.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SLS with:

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

2nd Resistance Point 4.84
1st Resistance Point 4.52
Last Price 4.20
1st Support Level 3.95
2nd Support Level 3.70

See More

52-Week High 94.00
Fibonacci 61.8% 59.63
Fibonacci 50% 49.01
Fibonacci 38.2% 38.39
Last Price 4.20
52-Week Low 4.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar